> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hospira Recalling 3 Labetalol Lots
- URL: https://www.fdaweb.com/hospira-recalling-3-labetalol-lots/
- Published: 2018-02-26T12:00:00.000Z
- Updated: 2026-09-14T23:25:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140839

FDA says Hospira is recalling three lots of labetalol hydrochloride injection 100 mg/20 mL vial and one lot of labetalol hydrochloride injection to the hospital/institution level due to discovery of cracks on the rim surface of vials for the lots, which is covered by the stopper and crimp seal. An agency recall [notice](https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm598114.htm?utm%5Fcampaign=Labetalol%20Hydrochloride%20Injection%20by%20Hospira%3A%20Recall&utm%5Fmedium=email&utm%5Fsource=Eloqua) says cracked vials may result in a lack of product sterility assurance.

The product was distributed nationwide to wholesalers/retailers/hospitals in the U.S. and Puerto Rico from 4/2017 to 8/2017.

Labetalol hydrochloride is an adrenergic receptor blocking agent indicated for controlling blood pressure in severe hypertension. It is administered by repeated intravenous injections or by slow intravenous infusion.